{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreid6vwczlhe5iobeuydmzudyuc3rphxweytvy6qftj2mjuntj6okqy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3merb4kxtyy62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiczccdp2xpv5ezhnft2pttme2lqliwhtya6xuulnlwbw2fkxgsyru"
    },
    "mimeType": "image/jpeg",
    "size": 445637
  },
  "path": "/news/2026-02-blood-based-strong-dementia-diagnosis.html",
  "publishedAt": "2026-02-13T12:40:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Alzheimer's disease & dementia"
  ],
  "textContent": "In a study published today, Friday, February 13, 2026, in the journal Nature Aging, researchers show that blood-based biomarkers can support accurate dementia diagnosis across diverse populations when integrated with cognitive and neuroimaging measures. Blood-based biomarkers are emerging as one of the most promising advances for the global diagnosis of dementia, including Alzheimer's disease and frontotemporal lobar degeneration. These tests offer a more accessible, scalable, and cost-effective alternative to traditional diagnostic tools such as brain imaging or cerebrospinal fluid analysis.",
  "title": "Blood-based tests show strong promise for dementia diagnosis—but population diversity matters"
}